List Biological Laboratories, Inc. is dedicated to providing research reagents to advance the understanding of disease and to further the development of vaccines, therapeutics and diagnostics. At the same time we are committed to exploiting the full potential of bacteria, their toxins, virulence factors and enzymes in treating infectious disease, developing cancer therapies and detecting potential threats. We welcome inquiries in these and other related areas.
List Labs has extensive experience producing bulk Drug Substances (DS) and Active Pharmaceutical Ingredients (API) as defined by Q7A Good Manufacturing Practice Guidance and current 21 CFR Parts 211, as well as facility design and technology transfer.
Since the intentional release of anthrax spores leading to lethal inhalational anthrax in 2001, the need for rapid and sensitive detection of infection has been critical. Unfortunately, early symptoms of infection are similar to those of common illnesses. While the symptoms are not remarkable, the Bacillus anthracis bacteria enter the patient’s blood stream and rapidly multiply. This expanding population of bacteria produces deadly proteins which will eventually overcome the patient. Classical techniques to detect and identify bacteria in blood take too long. We have devised a rapid method for detecting one of the proteins produced in the infection. This protein, anthrax lethal factor, is produced early in infection in a quantity sufficient for detection making it possible to rapidly determine that a patient is infected and to initiate therapy. A quick diagnosis is essential for successful treatment of the disease.
List Labs is looking to partner with an organization that can take this biotechnology to the level of application in the field. Please contact Dr. Shine if you’re interested in partnering.
List Labs has developed a process to make highly purified lipopolysaccharide from E. coli O113. LPS or Lipid A can be custom produced under cGMP guidelines in our laboratory for your clinical research program. We have a limited supply of cGMP LPS available for sale directly. This can be a dramatic cost savings over custom production.
We cultivate many bacterial strains to produce our reagents. A variety of bacteria, themselves, are currently of great interest because of their therapeutic potential. Do you have a strain which you would like produced for clinical trials?